Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.

Dr. Theriault outlines Cytophage’s expansion strategy, focusing on South Asia with a new product launch in Bangladesh and partnerships with major poultry integrators. He also touches on the development of phage-based vaccines and the company’s focus on both animal and human applications.

Looking ahead, Dr. Theriault highlights Cytophage’s goals: revenue generation, advancement of human clinical trials, and formation of strategic partnerships. These reflect the company’s ambition to capitalize on the growing interest in phage therapy.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Military Seizes Power in Madagascar After President Flees

Altamira Gold Hits 395.5 Metres Of 0.4 g/t Gold At Maria Bonita

Related News

Cytophage To Focus On Commercialization Efforts In 2024

Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a...
Tuesday, April 30, 2024, 10:13:02 AM

The Solution To Antibiotic Resistance – With Cytophage CEO Dr Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies. In this interview, Dr. Steven Theriault...

Thursday, February 22, 2024, 01:30:00 PM

Cytophage Reports Early Success In Single Subject Clinical Trial

Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted...
Tuesday, April 2, 2024, 09:05:42 AM

Cytophage Adds 30-Year Biotech Exec To Its Board

Cytophage Technologies (TSXV: CYTO) has added bench strength to its board of directors this morning,...
Monday, May 27, 2024, 09:09:36 AM

Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba

Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment...
Thursday, December 12, 2024, 05:14:00 PM